论文部分内容阅读
目的探讨婴幼儿呼吸道合胞病毒肺炎的药物治疗方案及临床应用效果。方法采用随机数字表法将120例婴幼儿呼吸道合胞病毒肺炎病例均分为对照组与实验组,两组分别应用干扰素、更昔洛韦治疗,观察两组临床疗效,检测患儿免疫功能指标。结果实验组治疗总有效率为98.3%,与对照组(83.3%)比较差异有统计学意义(P<0.05);治疗前后两组CD_4~+、CD_8~+、白细胞介素-2(IL-2)、B细胞、膜白细胞介素-2受体(mIL-2R)比较差异有统计学意义(P<0.05);两组治疗后CD_3~+、CD_4~+、CD_8~+、IL-2、B、m IL-2R比较差异未见统计学意义(P>0.05)。结论更昔洛韦治疗婴幼儿呼吸道合胞病毒肺炎效果显著,可有效改善患儿免疫功能指标,提高机体抵抗力,值得推广和应用。
Objective To explore the drug treatment of respiratory syncytial virus pneumonia in infants and young children and its clinical application. Methods A total of 120 cases of respiratory syncytial virus pneumonia in infants and young children were randomly divided into control group and experimental group using random number table. The two groups were treated with interferon and ganciclovir respectively. The clinical curative effect was observed and the immune function index. Results The total effective rate of the experimental group was 98.3%, which was significantly different from that of the control group (83.3%) (P <0.05). Before and after treatment, the levels of CD_4 +, CD_8 +, IL- 2, B lymphocytes and membrane interleukin-2 receptor (mIL-2R) had statistical significance (P <0.05) , B, m IL-2R difference was not statistically significant (P> 0.05). Conclusion Ganciclovir treatment of infantile respiratory syncytial virus pneumonia is significant, can effectively improve children with immune function, improve the body’s resistance, it is worth promoting and application.